Lusutrombopag

Lusutrombopag, sold under the brand name Mulpleta among others, is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts) such as thrombocytopenia associated with chronic liver disease in patients prior to elective invasive procedures.[1] It is being manufactured and marketed in Japan by Shionogi.[2][3][4] It was approved by the U.S. Food and Drug Administration (FDA) in July 2018, and NICE in January 2020.[5][6]

Lusutrombopag
Clinical data
Pronunciationloo" soo trom' boe pag
Trade namesMulpleta, Mulpleo
AHFS/Drugs.comMonograph
MedlinePlusa618043
License data
Routes of
administration
By mouth
ATC code
Legal status
Legal status
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Identifiers
IUPAC name
  • (E)-3-[2,6-Dichloro-4-[[4-[3-[(1S)-1-hexoxyethyl]-2-methoxyphenyl]-1,3-thiazol-2-yl]carbamoyl]phenyl]-2-methylprop-2-enoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC29H32Cl2N2O5S
Molar mass591.54 g·mol−1
3D model (JSmol)
SMILES
  • CCCCCCO[C@@H](C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(/C=C(\C)C(=O)O)c(Cl)c3)n2)c1OC
InChI
  • InChI=1S/C29H32Cl2N2O5S/c1-5-6-7-8-12-38-18(3)20-10-9-11-21(26(20)37-4)25-16-39-29(32-25)33-27(34)19-14-23(30)22(24(31)15-19)13-17(2)28(35)36/h9-11,13-16,18H,5-8,12H2,1-4H3,(H,35,36)(H,32,33,34)/b17-13+/t18-/m0/s1 Y
  • Key:NOZIJMHMKORZBA-KJCUYJGMSA-N Y
 NY (what is this?)

It was approved for medical use in the European Union in February 2019.[7]

References

  • "Lusutrombopag". Drug Information Portal. U.S. National Library of Medicine.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.